Literature DB >> 3036910

Bovine milk immunoglobulins for passive immunity to infantile rotavirus gastroenteritis.

H Brüssow, H Hilpert, I Walther, J Sidoti, C Mietens, P Bachmann.   

Abstract

Pregnant cows were successfully hyperimmunized with all four human rotavirus serotypes, resulting in a 100-fold increase in neutralizing milk antibody titers over those of controls. Milk antibodies were isolated batchwise from 1,000 kg of pooled milk for the first 10 lactation days, yielding 10 kg of freeze-dried milk immunoglobulin concentrate consisting of 50% bovine milk immunoglobulins. Milk immunoglobulin concentrate showed neutralizing activities against all four human rotavirus serotypes that were 100 times higher than those in pooled human milk samples and 10 times higher than those in a commercial pooled immunoglobulin preparation from pooled human blood serum. In vitro neutralization tests showed that milk immunoglobulin concentrate had powerful antiviral activity, even against very high doses of infectious rotaviruses. Because the technology of the milk immunoglobulin concentrate ensures that it is innocuous and can be used for oral application, it is proposed that milk immunoglobulin concentrate be used to induce passive immunity to infantile rotavirus gastroenteritis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3036910      PMCID: PMC269120          DOI: 10.1128/jcm.25.6.982-986.1987

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Levels of colostral antibodies against neonatal calf diaahoea virus.

Authors:  G N Woode; J Jones; J Bridger
Journal:  Vet Rec       Date:  1975-08-23       Impact factor: 2.695

Review 2.  Viral enteritis of calves.

Authors:  G N Woode; J C Bridger
Journal:  Vet Rec       Date:  1975-01-25       Impact factor: 2.695

3.  Secretory IgA, a major immunoglobulin in most bovine external secretions.

Authors:  J P Mach; J J Pahud
Journal:  J Immunol       Date:  1971-02       Impact factor: 5.422

4.  Recurrent rotavirus gastroenteritis.

Authors:  J Fonteyne; G Zissis; J P Lambert
Journal:  Lancet       Date:  1978-05-06       Impact factor: 79.321

5.  Occurrence of reo-like calf viruses in young children with acute gastroenteritis. Diagnoses established by electron microscopy and complement fixation, using the reo-like virus as antigen.

Authors:  B Tufvesson; T Johnsson
Journal:  Acta Pathol Microbiol Scand B       Date:  1976-02

6.  Human reovirus-like agent as the major pathogen associated with "winter" gastroenteritis in hospitalized infants and young children.

Authors:  A Z Kapikian; H W Kim; R G Wyatt; W L Cline; J O Arrobio; C D Brandt; W J Rodriguez; D A Sack; R M Chanock; R H Parrott
Journal:  N Engl J Med       Date:  1976-04-29       Impact factor: 91.245

7.  Prevention of rotavirus infection by oral administration of cow colostrum containing antihumanrotavirus antibody.

Authors:  T Ebina; A Sato; K Umezu; N Ishida; S Ohyama; A Oizumi; K Aikawa; S Katagiri; N Katsushima; A Imai
Journal:  Med Microbiol Immunol       Date:  1985       Impact factor: 3.402

8.  Viruses associated with acute gastroenteritis in young children.

Authors:  P J Middleton; M T Szymanski; M Petric
Journal:  Am J Dis Child       Date:  1977-07

9.  Reovirus-like agent as a cause of nosocomial diarrhea in infants.

Authors:  R W Ryder; J E McGowan; M H Hatch; E L Palmer
Journal:  J Pediatr       Date:  1977-05       Impact factor: 4.406

10.  Rotavirus infection in lambs: studies on passive protection.

Authors:  D R Snodgrass; P W Wells
Journal:  Arch Virol       Date:  1976       Impact factor: 2.574

View more
  20 in total

1.  Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate.

Authors:  D M Lyerly; E F Bostwick; S B Binion; T D Wilkins
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

Review 2.  Therapeutic potentials of bovine colostrums.

Authors:  B R Thapa
Journal:  Indian J Pediatr       Date:  2005-10       Impact factor: 1.967

3.  Pedimune in recurrent respiratory infection and diarrhoea--the Indian experience--the pride study.

Authors:  Kamlesh Patel; Rajiv Rana
Journal:  Indian J Pediatr       Date:  2006-07       Impact factor: 1.967

4.  Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine.

Authors:  M Warny; A Fatimi; E F Bostwick; D C Laine; F Lebel; J T LaMont; C Pothoulakis; C P Kelly
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

5.  Antibodies to seven rotavirus serotypes in cord sera, maternal sera, and colostrum of German women.

Authors:  H Brüssow; J Sidoti; L Lerner; H Rahim; W Eckstein; H Werchau; C Mietens
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

6.  A standard immunoglobulin preparation produced from bovine colostra shows antibody reactivity and neutralization activity against Shiga-like toxins and EHEC-hemolysin of Escherichia coli O157:H7.

Authors:  R Lissner; H Schmidit; H Karch
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

Review 7.  The immunology of parasite infections in immunocompromised hosts.

Authors:  T Evering; L M Weiss
Journal:  Parasite Immunol       Date:  2006-11       Impact factor: 2.280

8.  Bovine colostral antibody against verotoxin 2 derived from Escherichia coli O157:H7: resistance to proteases and effects in beagle dogs.

Authors:  Takashi Kuribayashi; Tetsuro Seita; Mariko Matsumoto; Katsunori Furuhata; Kazutoshi Tagata; Shizuo Yamamoto
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

9.  Murine intestinal antibody response to heterologous rotavirus infection.

Authors:  A A Merchant; W S Groene; E H Cheng; R D Shaw
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

10.  Bovine lactogenic immunity against cholera toxin-related enterotoxins and Vibrio cholerae outer membranes.

Authors:  M Boesman-Finkelstein; N E Walton; R A Finkelstein
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.